Pre-print abstract, talk to us about publication sponsorship opportunities Follow egnite on social:
Researchers became interested when preclinical studies demonstrated that adding glucagon receptor agonism to incretin-based therapy produced metabolic effects that exceeded those of GLP-1 or GIP activation aloneparticularly in energy expenditure and hepatic lipid metabolism
Experiments have been performed where volunteers were injected with l-nmma
Further, with a half life of less than 15 minutes, glutathione administered by IV may not raise levels in the long-term
A spokesperson for Novo Nordisk, the maker of Ozempic and Wegovy, said: Patient safety is a top priority for Novo Nordisk and we take all reports about adverse events from use of our medicines very seriously
See our Terms of Use, Privacy Notice, and Medical Consent for more details.